George DJ, Hessel C, Halabi S, et al. - Given that the phase II CABOSUN trial documented prolonged progression-free survival (PFS) and improved objective response rate (ORR) in relation to cabozantinib treatment vs sunitinib in patients with advanced renal cell carcinoma of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria, researchers focused on independent radiology committee-determined PFS and ORR by subgroups of baseline features in this present analysis. In the trial, 157 patients were treated with cabozantinib or sunitinib, using randomization stratified by IMDC risk group and the presence of bone metastases. Findings revealed a link of cabozantinib vs sunitinib treatment with improved PFS and ORR, generally, across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden.